Cosentyx (secukinumab) — United Healthcare
active enthesitis-related arthritis
Initial criteria
- Diagnosis of active enthesitis-related arthritis
- Patient is not receiving Cosentyx in combination with another targeted immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel (etanercept), Rinvoq (upadacitinib), Simponi (golimumab), Xeljanz (tofacitinib)]
Reauthorization criteria
- Documentation of positive clinical response to Cosentyx therapy
- Patient is not receiving Cosentyx in combination with another targeted immunomodulator [same list as above]
Approval duration
12 months